IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C

Abstract

IL28B variation is the strongest host factor not related to insulin resistance that determines outcome of antiviral therapy. Baseline platelet count predicts the outcome of antiviral therapy in CT allele patients.